8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors

A compound of formula (I)

• wherein
• B is selected from the group consisting of (C4-C8) heterocycloalkyl, heteroaryl, (C3-C8)cycloalkyl, and aryl wherein each of said cycloalkyl, heterocycloalkyl, heteroaryl and aryl may be optionally substituted by one or more group selected from (C1-C4)alkyl, halo, (C1-C4)haloalkyl, —(C1-C4)alkylene-NRARB, —NRARB, —NRAC(O)R1;
• —C(O)R1, —CN and (C3-C8)cycloalkyl, or
• each of said aryl may be fused to a second saturated or unsaturated ring optionally containing one or more heteroatoms selected from N, O and S to form a bicyclic ring system optionally substituted by one or more group selected from —C(O)R1, (C1-C4)alkyl and oxo;
• R1 is H or (C1-C4)alkyl;
• R2 is H or selected from the group consisting of (C1-C4)alkyl, (C1-C4)haloalkyl, —(C1-C4)alkylene-OR1 and (C3-C8)cycloalkyl;
• R3 is H or (C1-C4)alkyl;
• A is selected from the group consisting of 5-6 membered heteroaryl and aryl wherein each of said heteroaryl and aryl may be optionally substituted by one or more group selected from (C1-C4)alkyl, —C(O)R1, —C(O)OR1, —C(O)R1, (C1-C4)haloalkyl, halo, —NRAC(O)R1, —NRAC(O)OR1, —NRAC(O)—(C1-C4)alkylene-OR1, —NRAC(O)RC, —NRAC(O)NRARB, —NRAC(O)—(C1-C4)alkylene-NRARB, —N(C1-C4)alkylene-NRARB, aryl and heteroaryl optionally substituted by one or more (C1-C4)alkyl and (C1-C4)haloalkyl, or
• when A is aryl it may be fused to a second saturated or unsaturated ring optionally containing one or more heteroatoms selected from N, O and S to form a bicyclic ring system optionally substituted by one or more group selected from —C(O)R1, (C1-C4)alkyl and oxo;
• RC is selected from the group consisting of heteroaryl, aryl, (C3-C8) cycloalkyl and (C4-C8) heterocycloalkyl wherein said heteroaryl, aryl, heterocycloalkyl and cycloalkyl may be optionally substituted by one or more (C1-C4)alkyl and —C(O)OR1;
• RA and RB are at each occurrence independently H or selected from the group consisting of (C1-C4)alkyl, (C3-C8)cycloalkyl, (C1-C6)haloalkyl and halo, or
• RA and RB may form together with the nitrogen atom to which they are attached a 4-6 membered saturated heterocyclic ring system optionally containing a further heteroatom selected from N, S and O, said heterocyclic ring system may be optionally substituted by one or more groups selected from (C1-C4)alkyl, (C1-C4) haloalkyl and halo.